NO20041994L - Nye beta-fenyl-alfa-oksysubstituerte propion derivater: Fremgangsmate for deres fremstilling og deres anvendelse ved fremstilling av farmasoytisk riktige forbindelser - Google Patents

Nye beta-fenyl-alfa-oksysubstituerte propion derivater: Fremgangsmate for deres fremstilling og deres anvendelse ved fremstilling av farmasoytisk riktige forbindelser

Info

Publication number: NO20041994L
Authority: NO; Norway
Prior art keywords: preparation; propion; oxy; pharmaceutically; alpha
Prior art date: 2001-10-16

Application number

NO20041994A

Other languages

English (en)

Inventor

Ranjan Chakrabarti

Javed Iqbal

Debnath Bhuniva

Saibal Kumar Das

Gurram Ranga Madhavan

Mohan Chander

Sankar Mohan

Original Assignee

Reddys Lab Ltd Dr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-16

Filing date

2004-05-14

Publication date

2004-05-14

2004-05-14 Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr

2004-05-14 Publication of NO20041994L publication Critical patent/NO20041994L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Nutrition Science (AREA)
Child & Adolescent Psychology (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO20041994A 2001-10-16 2004-05-14 Nye beta-fenyl-alfa-oksysubstituerte propion derivater: Fremgangsmate for deres fremstilling og deres anvendelse ved fremstilling av farmasoytisk riktige forbindelser NO20041994L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN848CH2001		2001-10-16
PCT/IB2002/004274 WO2003033456A1 (en)	2001-10-16	2002-10-15	NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS

Publications (1)

Publication Number	Publication Date
NO20041994L true NO20041994L (no)	2004-05-14

Family

ID=11097010

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20041994A NO20041994L (no)	2001-10-16	2004-05-14	Nye beta-fenyl-alfa-oksysubstituerte propion derivater: Fremgangsmate for deres fremstilling og deres anvendelse ved fremstilling av farmasoytisk riktige forbindelser
NO20041998A NO20041998L (no)	2001-10-16	2004-05-14	Benzoksazin og benzotiazinderivater og farmasoytiske sammensetninger som inneholder dem

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20041998A NO20041998L (no)	2001-10-16	2004-05-14	Benzoksazin og benzotiazinderivater og farmasoytiske sammensetninger som inneholder dem

Country Status (14)

Country	Link
US (2)	US7365064B2 (no)
EP (2)	EP1436247A1 (no)
JP (2)	JP2005505617A (no)
CN (2)	CN1589258A (no)
BR (2)	BR0213350A (no)
CA (2)	CA2463685A1 (no)
HR (2)	HRP20040349A2 (no)
HU (2)	HUP0401649A3 (no)
IL (2)	IL161431A0 (no)
NO (2)	NO20041994L (no)
NZ (1)	NZ532285A (no)
PL (2)	PL369655A1 (no)
WO (2)	WO2003033481A1 (no)
ZA (2)	ZA200402858B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005040102A2 (en) *	2003-10-28	2005-05-06	Dr. Reddy's Laboratories Ltd.	Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
EP2305352A1 (en)	2004-04-02	2011-04-06	Merck Sharp & Dohme Corp.	5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
ITRM20050390A1 (it)	2005-07-22	2007-01-23	Giuliani Spa	Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it)	2005-07-22	2007-01-23	Giuliani Spa	Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
JP2009536954A (ja) *	2006-05-11	2009-10-22	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｃｅｔｐ阻害剤としての３，４−ジヒドロ−２ｈ−ベンゾ［１，４］オキサジンおよびチアジン誘導体
WO2008079427A1 (en)	2006-05-11	2008-07-03	Janssen Pharmaceutica N.V.	1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors
US11241420B2 (en)	2007-04-11	2022-02-08	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
EP3788877B1 (en) *	2007-04-11	2024-08-07	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en)	2007-04-11	2016-11-17	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en)	2007-06-04	2020-10-20	Kunwar Shailubhai	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2328910B1 (en)	2008-06-04	2014-08-06	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2348857B1 (en)	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
UA107562C2 (uk)	2008-12-05	2015-01-26		Спосіб лікування псоріазу
BRPI1011226B1 (pt)	2009-02-16	2019-10-29	Giuliani Internacional Ltd	uso de uma composição farmacêutica para tratar condições relacionadas ao cabelo
JP2013520502A (ja)	2010-02-25	2013-06-06	メルク・シャープ・エンド・ドーム・コーポレイション	有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
AU2011254726B2 (en)	2010-05-19	2014-03-06	Upfield Europe B.V.	Theobromine for increasing HDL-cholesterol
US20130156720A1 (en)	2010-08-27	2013-06-20	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
JP5728099B2 (ja)	2011-02-25	2015-06-03	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体
WO2013082106A1 (en)	2011-12-02	2013-06-06	The General Hospital Corporation	Differentiation into brown adipocytes
CN109999017A (zh)	2012-02-09	2019-07-12	诺格拉制药有限公司	治疗纤维化的方法
CA2870490A1 (en)	2012-04-18	2013-10-24	Nogra Pharma Limited	Methods of treating lactose intolerance
RU2015106909A (ru)	2012-08-02	2016-09-27	Мерк Шарп И Доум Корп.	Антидиабетические трициклические соединения
WO2014130608A1 (en)	2013-02-22	2014-08-28	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
EP2970119B1 (en)	2013-03-14	2021-11-03	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
HK1220611A1 (zh)	2013-03-15	2017-05-12	Bausch Health Ireland Limited	用於治疗胃肠道病症的组成物
US9896599B2 (en) *	2013-04-30	2018-02-20	3M Innovative Properties Company	Process for preparing poly(benzoxazines)
CN113388007A (zh)	2013-06-05	2021-09-14	博士医疗爱尔兰有限公司	鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
DK3166923T3 (da)	2014-07-10	2023-04-11	SpecGx LLC	Fremgangsmåde til fremstilling af substituerede phenylalkaner
EP3551176A4 (en)	2016-12-06	2020-06-24	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
DK3921299T3 (da)	2019-02-08	2025-01-27	Nogra Pharma Ltd	Proces til fremstilling af 3-(4'-aminophenyl)-2-methoxypropionsyre samt analoger og intermediater deraf
CN113968781A (zh) *	2021-11-11	2022-01-25	上海吉奉生物科技有限公司	一种(s)-2-羟基-3-邻甲基丙酸的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0816316A4 (en) *	1995-03-10	1999-06-02	Nitto Chemical Industry Co Ltd	Process for producing 1,2-ethanediol derivatives
NZ504106A (en) *	1998-05-27	2003-02-28	Dr	Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
US7348426B1 (en)	1999-04-28	2008-03-25	Dr. Reddy's Laboraties Limited	Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
SE9904421D0 (sv) *	1999-12-03	1999-12-03	Astra Ab	New compounds
WO2002030914A1 (en) *	2000-10-12	2002-04-18	Dr. Reddy's Research Foundation	Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them

2002
- 2002-10-15 CA CA002463685A patent/CA2463685A1/en not_active Abandoned
- 2002-10-15 IL IL16143102A patent/IL161431A0/xx unknown
- 2002-10-15 NZ NZ532285A patent/NZ532285A/en unknown
- 2002-10-15 HU HU0401649A patent/HUP0401649A3/hu unknown
- 2002-10-15 JP JP2003536197A patent/JP2005505617A/ja active Pending
- 2002-10-15 BR BR0213350-4A patent/BR0213350A/pt not_active IP Right Cessation
- 2002-10-15 WO PCT/IB2002/004275 patent/WO2003033481A1/en not_active Ceased
- 2002-10-15 US US10/492,454 patent/US7365064B2/en not_active Expired - Fee Related
- 2002-10-15 HR HR20040349A patent/HRP20040349A2/hr not_active Application Discontinuation
- 2002-10-15 EP EP02801466A patent/EP1436247A1/en not_active Withdrawn
- 2002-10-15 CN CNA028227239A patent/CN1589258A/zh active Pending
- 2002-10-15 WO PCT/IB2002/004274 patent/WO2003033456A1/en not_active Ceased
- 2002-10-15 CN CNA028238222A patent/CN1596249A/zh active Pending
- 2002-10-15 JP JP2003536221A patent/JP2005527480A/ja not_active Withdrawn
- 2002-10-15 BR BR0213380-6A patent/BR0213380A/pt not_active Application Discontinuation
- 2002-10-15 EP EP02775090A patent/EP1436268A1/en not_active Withdrawn
- 2002-10-15 IL IL16142902A patent/IL161429A0/xx unknown
- 2002-10-15 US US10/492,452 patent/US20110105748A1/en not_active Abandoned
- 2002-10-15 CA CA002463686A patent/CA2463686A1/en not_active Abandoned
- 2002-10-15 HU HU0401647A patent/HUP0401647A3/hu unknown
- 2002-10-15 HR HR20040350A patent/HRP20040350A2/xx not_active Application Discontinuation
- 2002-10-15 PL PL02369655A patent/PL369655A1/xx not_active Application Discontinuation
- 2002-10-15 PL PL02369732A patent/PL369732A1/xx not_active Application Discontinuation
2004
- 2004-04-15 ZA ZA200402858A patent/ZA200402858B/xx unknown
- 2004-04-16 ZA ZA200402910A patent/ZA200402910B/en unknown
- 2004-05-14 NO NO20041994A patent/NO20041994L/no not_active Application Discontinuation
- 2004-05-14 NO NO20041998A patent/NO20041998L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0401649A3 (en)	2007-05-29
CN1589258A (zh)	2005-03-02
JP2005505617A (ja)	2005-02-24
IL161431A0 (en)	2004-09-27
ZA200402858B (en)	2005-01-12
IL161429A0 (en)	2004-09-27
HRP20040349A2 (en)	2005-06-30
HUP0401647A2 (hu)	2004-11-29
NO20041998L (no)	2004-07-02
JP2005527480A (ja)	2005-09-15
US20050113368A1 (en)	2005-05-26
ZA200402910B (en)	2005-01-13
NZ532285A (en)	2005-11-25
CN1596249A (zh)	2005-03-16
PL369655A1 (en)	2005-05-02
NO20041998D0 (no)	2004-05-14
HUP0401649A2 (hu)	2004-11-29
EP1436247A1 (en)	2004-07-14
HUP0401647A3 (en)	2008-05-28
CA2463686A1 (en)	2003-04-24
BR0213380A (pt)	2005-02-01
BR0213350A (pt)	2004-10-13
EP1436268A1 (en)	2004-07-14
HRP20040350A2 (en)	2005-06-30
WO2003033456A1 (en)	2003-04-24
US20110105748A1 (en)	2011-05-05
WO2003033481A1 (en)	2003-04-24
US7365064B2 (en)	2008-04-29
PL369732A1 (en)	2005-05-02
CA2463685A1 (en)	2003-04-24

Publication	Publication Date	Title
NO20041994L (no)	2004-05-14	Nye beta-fenyl-alfa-oksysubstituerte propion derivater: Fremgangsmate for deres fremstilling og deres anvendelse ved fremstilling av farmasoytisk riktige forbindelser
NO20024808L (no)	2002-10-04	FremgangsmÕte ved syntesen av perindopril og farmasöytisk akseptable salter derav
NO20030844D0 (no)	2003-02-24	Fremgangsmåte for fremstilling av N-aryl-antranilinsyrer og derivater derav
NO20015156D0 (no)	2001-10-22	5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse
NO20031694L (no)	2003-04-11	Krystallinsk monohydrat, fremgangsmåte for fremstilling derav og anvendelsederav til fremstilling av et medikament
NO20032726L (no)	2003-06-16	Kinazolinderivater, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstilling derav
NO20024176L (no)	2002-10-29	Farmasöytiske preparater inneholder derivater av 3-amino- azetidin, de nye derivater og deres fremstilling
NO20024623L (no)	2002-11-08	Ny fremgangsmÕte for fremstilling av kondensert imidazopyridinderivat og ny krystallform
NO20025029L (no)	2002-10-18	Nye epotilonderivater, fremgangsmÕte for fremstilling derav og deres farmasöytiske anvendelse
NO20023400D0 (no)	2002-07-15	Nye forbindelser med lipid- og kolesterolnedsettende virkning, fremgangsmåte ved deres fremstilling og farmasöytiskpreparat
DK1674456T3 (da)	2008-10-27	Nye 1,4-benzothiazepin-1,1-dioxid-derivater med forbedrede egenskaber, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20013569L (no)	2001-07-19	Fremgangsmate ved fremstilling av L-fenylephrine-hydroklorid
NO20023662L (no)	2002-09-27	Nye heterocykliske derivater, fremgangsmåte ved fremstilling og farmasöytiske sammensetninger inneholdende det samme
NO20033433D0 (no)	2003-08-01	Fremgangsmåte for fremstilling av 2-(2-pyridylmetyl)sulfinyl- 1H-benzimidasol
NO326689B1 (no)	2009-01-26	Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene
NO20003555L (no)	2002-01-11	Fremgangsmåte ved fremstilling av konstruksjonselementer og de resulterende elementer
NO20032340D0 (no)	2003-05-23	Substituerte derivater av aminofuran-2-yl-eddiksyre og aminotien-2-yl-eddiksyre og deres anvendelse for behandling av migrene og smerte
NO20031754L (no)	2003-04-15	Fremgangsmåte for fremstilling av mesylater av piperzinderivater
NO20025069L (no)	2002-10-22	Ny stabil krystall av tiazolidindionderivat og fremgangsmÕte for fremstilling av det samme
NO20042640L (no)	2004-06-23	Fremgangsmate for fremstilling av ekinocandinderivater
NO20035538D0 (no)	2003-12-11	Fremgangsmåte for fremstilling av zaleplon
NO20030515L (no)	2003-03-31	Fremgangsmåte for fremstilling av dinapsolin
NO20035586L (no)	2003-12-15	Fremgangsmate for fremstilling av cykloheksanol-derivater
DK1353912T3 (da)	2006-01-09	2-Arylimino-2,3-dihydrothiazolderivater, fremgangsmåderne til deres fremstilling og deres terapeutiske anvendelse
DK1212336T3 (da)	2004-03-15	Fremgangsmåde til fremstilling af sfæriske agglomerater af telithromycin og deres anvendelse ved fremstilling af farmaceutiske former

Legal Events

Date	Code	Title	Description
2008-05-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application